Literature DB >> 33166735

Dysbiosis is one of the risk factor for stroke and cognitive impairment and potential target for treatment.

Magdalena Koszewicz1, Joanna Jaroch2, Anna Brzecka3, Maria Ejma1, Slawomir Budrewicz1, Liudmila M Mikhaleva4, Cristian Muresanu5, Pamela Schield6, Siva G Somasundaram7, Cecil E Kirkland7, Marco Avila-Rodriguez8, Gjumrakch Aliev9.   

Abstract

More than 50 million people have various forms of cognitive impairment basically caused by neurodegenerative diseases, such as Alzheimer's, Parkinson's, and cerebrovascular diseases as well as stroke. Often these conditions coexist and exacerbate one another. The damaged area in post-stroke dementia may lead to neurodegenerative lesions. Gut microbiome functions like an endocrine organ by generating bioactive metabolites that can directly or indirectly impact human physiology. An alteration in the composition and function of intestinal flora, i.e. gut dysbiosis, is implicated in neurodegenerative and cerebrovascular diseases. Additionally, gut dysbiosis may accelerate the progression of cognitive impairment. Dysbiosis may result from obesity; metabolic disorders, cardiovascular disease, and sleep disorders, Lack of physical activity is associated with dysbiosis as well. These may coexist in various patterns in older people, enhancing the risk, incidence, and progression of cerebrovascular lesions, neurodegenerative disorders, and cognitive impairment, creating a vicious circle. Recently, it has been reported that several metabolites produced by gut microbiota (e.g., trimethylamine/trimethylamine N-oxide, short-chain fatty acids, secondary bile acids) may be linked to neurodegenerative and cerebrovascular diseases. New treatment modalities, including prebiotic and probiotics, may normalize the gut microbiota composition, change the brain-gut barrier, and decrease the risk of the pathology development. Fecal microbiota transplantation, sometimes in combination with other methods, is used for remodeling and replenishing the symbiotic gut microbiome. This promising field of research is associated with basic findings of bidirectional communication between body organs and gut microbiota that creates new possibilities of pharmacological treatments of many clinical conditions. The authors present the role of gut microbiota in physiology, and the novel therapeutic targets in modulation of intestinal microbiota Personalized therapies based on their personal genome make up could offer benefits by modulating microbiota cross-talk with brain and cardiovascular system. A healthy lifestyle, including pre and probiotic nutrition is generally recommended. Prevention may also be enhanced by correcting gut dysbiosis resulting a reduced risk of post-stroke cognitive impairment including dementia.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cognitive impairment; Microbiome; Neurodegeneration; Nutrition; Obesity; Stroke

Year:  2020        PMID: 33166735     DOI: 10.1016/j.phrs.2020.105277

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  10 in total

1.  Analysis of Changes of Intestinal Flora in Elderly Patients with Alzheimer's Disease and Liver Cancer and Its Correlation with Abnormal Gastrointestinal Motility.

Authors:  Weiwei Zhang; Xuelian Zhang; Yanyan Zhang; Huanyu Wu; Qiaoling Liu; Xinyu Zhou; Yunxia Meng
Journal:  J Oncol       Date:  2021-08-13       Impact factor: 4.375

Review 2.  Novel Mechanisms and Therapeutic Targets for Ischemic Stroke: A Focus on Gut Microbiota.

Authors:  Zeyu Bao; Zeyu Zhang; Guoyang Zhou; Anke Zhang; Anwen Shao; Feng Zhou
Journal:  Front Cell Neurosci       Date:  2022-05-17       Impact factor: 6.147

Review 3.  Immunotherapy and Microbiota for Targeting of Liver Tumor-Initiating Stem-like Cells.

Authors:  Keigo Machida; Stanley M Tahara
Journal:  Cancers (Basel)       Date:  2022-05-12       Impact factor: 6.575

Review 4.  Impact of Exercise on Gut Microbiota in Obesity.

Authors:  Jerónimo Aragón-Vela; Patricio Solis-Urra; Francisco Javier Ruiz-Ojeda; Ana Isabel Álvarez-Mercado; Jorge Olivares-Arancibia; Julio Plaza-Diaz
Journal:  Nutrients       Date:  2021-11-10       Impact factor: 5.717

5.  Distinctive Gut Microbiota Alteration Is Associated with Poststroke Functional Recovery: Results from a Prospective Cohort Study.

Authors:  Yini Dang; Xintong Zhang; Yu Zheng; Binbin Yu; Dijia Pan; Xiaomin Jiang; Chengjie Yan; Qiuyu Yu; Xiao Lu
Journal:  Neural Plast       Date:  2021-12-07       Impact factor: 3.599

Review 6.  Roles of α‑synuclein in gastrointestinal microbiome dysbiosis‑related Parkinson's disease progression (Review).

Authors:  Qingchun Lei; Tingting Wu; Jin Wu; Xiaogang Hu; Yingxia Guan; Ying Wang; Jinyuan Yan; Guolin Shi
Journal:  Mol Med Rep       Date:  2021-08-20       Impact factor: 2.952

7.  Predicted Cognitive Conversion in Guiding Early Decision-Tailoring on Patients With Cognitive Impairment.

Authors:  Yu Zheng; Yin Liu; Jiawen Wu; Yi Xie; Siyu Yang; Wanting Li; Huaiqing Sun; Qing He; Ting Wu
Journal:  Front Aging Neurosci       Date:  2022-02-02       Impact factor: 5.750

Review 8.  The Influence of Gut Dysbiosis in the Pathogenesis and Management of Ischemic Stroke.

Authors:  Saravana Babu Chidambaram; Annan Gopinath Rathipriya; Arehally M Mahalakshmi; Sonali Sharma; Tousif Ahmed Hediyal; Bipul Ray; Tuladhar Sunanda; Wiramon Rungratanawanich; Rajpal Singh Kashyap; M Walid Qoronfleh; Musthafa Mohamed Essa; Byoung-Joon Song; Tanya M Monaghan
Journal:  Cells       Date:  2022-04-06       Impact factor: 6.600

9.  Effects of lactoferrin on intestinal flora of metabolic disorder mice.

Authors:  Li Li; Chunli Ma; Hong Yuan; Ruiping Hu; Wuji Wang
Journal:  BMC Microbiol       Date:  2022-07-22       Impact factor: 4.465

Review 10.  The Microbiota-Gut-Brain Axis and Alzheimer Disease. From Dysbiosis to Neurodegeneration: Focus on the Central Nervous System Glial Cells.

Authors:  Maria Grazia Giovannini; Daniele Lana; Chiara Traini; Maria Giuliana Vannucchi
Journal:  J Clin Med       Date:  2021-05-27       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.